Immunome Inc (NASDAQ: IMNM) kicked off on Friday, down -3.46% from the previous trading day, before settling in for the closing price of $8.95. Over the past 52 weeks, IMNM has traded in a range of $5.15-$16.81.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -38.15%. While this was happening, its average annual earnings per share was recorded 56.81%. With a float of $76.80 million, this company’s outstanding shares have now reached $86.96 million.
Let’s determine the extent of company efficiency that accounts for 118 employees. In terms of profitability, gross margin is 100.0%, operating margin of -1994.3%, and the pretax margin is -1875.21%.
Immunome Inc (IMNM) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Immunome Inc is 11.74%, while institutional ownership is 82.25%. The most recent insider transaction that took place on Jun 03 ’25, was worth 46,900. In this transaction Director of this company bought 5,000 shares at a rate of $9.38, taking the stock ownership to the 36,415 shares. Before that another transaction happened on Mar 25 ’25, when Company’s Director bought 7,800 for $7.78, making the entire transaction worth $60,684. This insider now owns 31,415 shares in total.
Immunome Inc (IMNM) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 56.81% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.72% during the next five years compared to -38.15% drop over the previous five years of trading.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Take a look at Immunome Inc’s (IMNM) current performance indicators. Last quarter, stock had a quick ratio of 10.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 68.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.19, a number that is poised to hit -0.51 in the next quarter and is forecasted to reach -2.36 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Looking closely at Immunome Inc (NASDAQ: IMNM), its last 5-days average volume was 1.04 million, which is a drop from its year-to-date volume of 1.06 million. As of the previous 9 days, the stock’s Stochastic %D was 48.04%.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 63.10%, which indicates a significant increase from 31.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.47 in the past 14 days, which was lower than the 0.57 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.67, while its 200-day Moving Average is $10.07. However, in the short run, Immunome Inc’s stock first resistance to watch stands at $8.85. Second resistance stands at $9.07. The third major resistance level sits at $9.19. If the price goes on to break the first support level at $8.51, it is likely to go to the next support level at $8.39. Now, if the price goes above the second support level, the third support stands at $8.17.
Immunome Inc (NASDAQ: IMNM) Key Stats
The company with the Market Capitalisation of 751.79 million has total of 87,012K Shares Outstanding. Its annual sales at the moment are 9,040 K in contrast with the sum of -292,960 K annual income. Company’s last quarter sales were recorded 2,930 K and last quarter income was -41,640 K.
